

# xiaorui Fu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9949246/publications.pdf>

Version: 2024-02-01

66  
papers

1,034  
citations

471061

17  
h-index

500791

28  
g-index

70  
all docs

70  
docs citations

70  
times ranked

1493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	6.9	155
2	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , 2016, 22, 5223-5228.	3.2	112
3	Recurrent PDGFRB mutations in unicentric Castleman disease. <i>Leukemia</i> , 2019, 33, 1035-1038.	3.3	48
4	Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. <i>Oncotarget</i> , 2017, 8, 72182-72196.	0.8	43
5	c-myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12628-12637.	1.2	36
6	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , 2019, 20, 31-41.	1.5	32
7	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , 2018, 16, 1275-1284.	0.8	28
8	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. <i>Investigational New Drugs</i> , 2020, 38, 1847-1853.	1.2	28
9	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus <sc>CHOP</sc> in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2017, 178, 772-780.	1.2	25
10	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , 2019, 10, 4209.	5.8	25
11	Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. <i>Scientific Reports</i> , 2017, 7, 41057.	1.6	23
12	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 406-410.	1.2	22
13	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. <i>Journal of Neuro-Oncology</i> , 2018, 140, 427-434.	1.4	22
14	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 53808-53819.	0.8	21
15	Efficacy and Safety of a Pegasparginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2022, 8, 1035.	3.4	21
16	Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1522-1529.	1.9	19
17	TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/ $\beta$ -catenin pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 7.	1.8	19
18	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. <i>Oncotarget</i> , 2016, 7, 55721-55731.	0.8	19

#	ARTICLE	IF	CITATIONS
19	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. <i>Leukemia Research</i> , 2015, 39, 1448-1454.	0.4	18
20	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. <i>Molecular Medicine</i> , 2018, 24, 35.	1.9	18
21	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. <i>Experimental Cell Research</i> , 2018, 364, 125-132.	1.2	14
22	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. <i>Oncology Letters</i> , 2016, 11, 693-698.	0.8	13
23	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. <i>Scientific Reports</i> , 2018, 8, 12907.	1.6	13
24	&lt;p&gt;Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7189-7197.	1.0	13
25	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3026-3026.	0.8	13
26	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 3829-3829.	0.6	13
27	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2613-2618.	0.6	12
28	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. <i>Oncology Letters</i> , 2016, 12, 4173-4180.	0.8	12
29	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1509-1516.	0.8	11
30	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labeled Study with Ddgp Regimen Versus SMILE Regimen. <i>Blood</i> , 2019, 134, 463-463.	0.6	11
31	Platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ) is overexpressed in NK/T-cell lymphoma and mediates cell survival. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 525-531.	1.0	10
32	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 1470-1477.	2.3	10
33	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 16213-16219.	0.8	10
34	&lt;p&gt;Clinical features and prognostic factors of primary bone marrow lymphoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2553-2563.	0.9	9
35	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , 2020, 133, 109301.	1.2	9
36	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092382.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. <i>Frontiers in Oncology</i> , 2021, 11, 687374.	1.3	9
38	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , 2021, 53, 837-846.	1.3	9
39	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. <i>Oncology Letters</i> , 2015, 10, 3261-3265.	0.8	8
40	MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. <i>Anti-Cancer Drugs</i> , 2018, 29, 861-870.	0.7	8
41	Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. <i>Oncology Letters</i> , 2018, 16, 6624-6632.	0.8	8
42	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> , 2019, Volume 11, 1363-1372.	0.9	8
43	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , 2021, 14, 405-411.	1.5	8
44	Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes. <i>Medicine (United States)</i> , 2017, 96, e7111.	0.4	7
45	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. <i>Haematologica</i> , 2020, 105, e107-e110.	1.7	7
46	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 33-43.	1.2	6
47	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 275-284.	2.0	6
48	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. <i>Aging</i> , 2019, 11, 3939-3957.	1.4	6
49	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. <i>Oncology Letters</i> , 2014, 8, 886-890.	0.8	4
50	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. <i>Cancer Cell International</i> , 2018, 18, 150.	1.8	3
51	Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system. <i>Hematological Oncology</i> , 2023, 41, 267-274.	0.8	3
52	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 686595.	1.8	3
53	ORP8 induces apoptosis by releasing cytochrome c from mitochondria in non-small cell lung cancer. <i>Oncology Reports</i> , 2020, 43, 1516-1524.	1.2	3
54	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2021, 138, 3830-3830.	0.6	3

#	ARTICLE	IF	CITATIONS
55	CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes. <i>Leukemia Research</i> , 2022, 117, 106840.	0.4	3
56	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2018, 15, 8034-8038.	0.8	2
57	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 42-50.	0.3	2
58	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. <i>Cancer Biology and Medicine</i> , 2021, 19, 1089-1099.	1.4	1
59	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial. <i>Blood</i> , 2021, 138, 1368-1368.	0.6	1
60	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). <i>Blood</i> , 2016, 128, 2989-2989.	0.6	0
61	Primary Testicular Lymphoma:a Single Center Experience and Literature Review. <i>Blood</i> , 2016, 128, 5415-5415.	0.6	0
62	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. <i>Blood</i> , 2019, 134, 2873-2873.	0.6	0
63	Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8018-8018.	0.8	0
64	Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
65	Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial. <i>Blood</i> , 2020, 136, 5-5.	0.6	0
66	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. <i>Leukemia and Lymphoma</i> , 2022, , 1-6.	0.6	0